The U.S. FDA has recently approved Inluriyo (imlunestrant), a new oral therapy from Eli Lilly, for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in adults whose disease has progressed after previous endocrine therapy.
Inluriyo works as a selective estrogen receptor degrader (SERD). It not only blocks the estrogen receptor but also helps break it down. This makes it effective for patients whose cancers have stopped responding to older hormonal treatments due to ESR1 mutations.
Results from the Phase 3 EMBER-3 trial showed that Inluriyo improved progression-free survival to about 5.5 months, compared to 3.8 months with standard hormonal options like fulvestrant or exemestane. Patients also had higher response rates, showing that the drug can make a real difference.
The most common side effects were fatigue, nausea, muscle pain, and mild liver enzyme changes. While some side effects were reported, its once-daily oral dose offers greater comfort and convenience for patients compared to injections.
This approval brings new hope for women with advanced breast cancer by offering a treatment that continues to work when traditional therapies no longer do.
This is a heartening development for patients and families affected by advanced breast cancer. The approval of Inluriyo offers renewed hope and comfort, showing how science continues to find new ways to extend life and improve its quality for those who need it most.
Inluriyo, a new oral SERD, improves outcomes in ESR1-mutated advanced ER-positive, HER2-negative breast cancer after prior endocrine therapy, with manageable side effects.
How does Inluriyo compare to existing SERDs in real-world effectiveness and patient quality of life?
Inluriyo shows promising real-world advantages over existing SERDs, offering improved progression-free survival and the convenience of oral dosing, which could meaningfully enhance patient quality of life.
Absolutely Manisha! Inluriyo’s oral formulation truly stands out it not only simplifies treatment but also improves adherence and overall patient comfort. If the ongoing trials continue to show consistent efficacy, it could redefine the standard of care for patients needing SERD therapy.
Inluriyo’s oral formulation truly stands out it not only simplifies treatment but also improves adherence and overall patient comfort. If the ongoing trials continue to show consistent efficacy, it could redefine the standard of care for patients needing SERD therapy.